MX2010005676A - Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. - Google Patents

Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.

Info

Publication number
MX2010005676A
MX2010005676A MX2010005676A MX2010005676A MX2010005676A MX 2010005676 A MX2010005676 A MX 2010005676A MX 2010005676 A MX2010005676 A MX 2010005676A MX 2010005676 A MX2010005676 A MX 2010005676A MX 2010005676 A MX2010005676 A MX 2010005676A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
delaying
onset
clinically definite
definite multiple
Prior art date
Application number
MX2010005676A
Other languages
English (en)
Inventor
Yafit Stark
David Ladkani
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40678899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010005676(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2010005676A publication Critical patent/MX2010005676A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para retrasar el comienzo de esclerosis múltiple clínicamente determinada, en un paciente en riesgo de desarrollar esclerosis múltiple clínicamente determinada, y para atrasar el progreso a largo plazo de esclerosis múltiple y sus síntomas, el método comprende administrar periódicamente al paciente una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de acetato de glatirámero, retrasando de este modo en el paciente el comienzo de esclerosis múltiple clínicamente determinada, y atrasando el progreso a largo plazo de esclerosis múltiple y sus síntomas.
MX2010005676A 2007-11-28 2008-11-26 Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. MX2010005676A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US471007P 2007-11-28 2007-11-28
US527107P 2007-12-03 2007-12-03
US714107P 2007-12-11 2007-12-11
US19245508P 2008-09-17 2008-09-17
PCT/US2008/013146 WO2009070298A1 (en) 2007-11-28 2008-11-26 Method of delaying the onset of clinically definite multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2010005676A true MX2010005676A (es) 2010-08-06

Family

ID=40678899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005676A MX2010005676A (es) 2007-11-28 2008-11-26 Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.

Country Status (12)

Country Link
US (2) US20090149541A1 (es)
EP (1) EP2111105A4 (es)
JP (1) JP2011504925A (es)
KR (1) KR20100102620A (es)
CN (1) CN101877963A (es)
AU (1) AU2008330093A1 (es)
BR (1) BRPI0819001A2 (es)
CA (1) CA2702437C (es)
EA (1) EA201070656A1 (es)
IL (1) IL205856A0 (es)
MX (1) MX2010005676A (es)
WO (1) WO2009070298A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
CA2463816C (en) 2001-10-19 2014-07-08 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
RU2419638C2 (ru) * 2005-02-02 2011-05-27 Тева Фармасьютикал Индастриз, Лтд. Способ получения полипептидных смесей с использованием гидрогенолиза
SI1848415T1 (sl) * 2005-02-17 2013-08-30 Teva Pharmaceutical Industries Ltd. Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US9206206B2 (en) * 2008-11-06 2015-12-08 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
DK2275086T3 (da) 2009-07-15 2012-07-09 Teva Pharma Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
PL2949335T3 (pl) * 2009-08-20 2017-07-31 Yeda Research & Development Company, Ltd. Terapia octanem glatirameru podawanym z niewielką częstotliwością
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2011083465A1 (en) * 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Treatment with vb-201
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MX347871B (es) 2010-10-11 2017-05-16 Teva Pharmaceutical Ind Ltd * Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
SG11201401921YA (en) 2011-10-31 2014-05-29 Xeris Pharmaceuticals Inc Formulations for the treatment of diabetes
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
CN106573106B (zh) 2014-08-06 2021-06-22 Xeris药物公司 用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
CN106999506A (zh) 2014-11-26 2017-08-01 脉管生物生长有限公司 氧化脂质以及纤维化的治疗或预防
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU780188B2 (en) * 2000-01-20 2005-03-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
ES2349033T3 (es) * 2001-12-04 2010-12-22 Teva Pharmaceutical Industries, Ltd. Procedimientos para la medida de la actividad del acetato de glatiramer.
US20040048871A1 (en) * 2002-09-09 2004-03-11 Rowe Vernon D. Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous system
CA2541445A1 (en) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries Ltd. Nanoparticles for drug delivery
US20050220764A1 (en) * 2004-04-01 2005-10-06 Schering Aktiengesellschaft Higher-doses of interferon-beta for treatment of multiple sclerosis
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
PT2361924E (pt) * 2004-09-09 2014-03-13 Teva Pharma Processo para a preparação de misturas de acetato de glatirâmero trifluoroacetiílico utilizando ácido bromídrico purificado
PL1797109T3 (pl) * 2004-09-09 2016-11-30 Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
RU2419638C2 (ru) * 2005-02-02 2011-05-27 Тева Фармасьютикал Индастриз, Лтд. Способ получения полипептидных смесей с использованием гидрогенолиза
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis

Also Published As

Publication number Publication date
CA2702437A1 (en) 2009-06-04
KR20100102620A (ko) 2010-09-24
JP2011504925A (ja) 2011-02-17
WO2009070298A1 (en) 2009-06-04
AU2008330093A1 (en) 2009-06-04
WO2009070298A9 (en) 2010-07-01
EP2111105A1 (en) 2009-10-28
IL205856A0 (en) 2010-11-30
EA201070656A1 (ru) 2010-12-30
CA2702437C (en) 2013-06-25
CN101877963A (zh) 2010-11-03
EP2111105A4 (en) 2011-05-04
BRPI0819001A2 (pt) 2014-10-07
US20100305023A1 (en) 2010-12-02
US20090149541A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
MX2010005676A (es) Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
NZ623495A (en) Oral formulations of cytidine analogs and methods of use thereof
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
NZ702801A (en) Treatment of sanfilippo syndrome type b
UA111599C2 (uk) Композиція каспофунгіну
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
WO2008152822A1 (ja) 医薬
MX352647B (es) Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato.
TN2012000046A1 (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorfers
NO20082636L (no) Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
WO2014194226A3 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
RU2011113762A (ru) Способы применения композиций с замедленным высвобождением аминопиридина
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: YEDA RESEARCH AND DEVELOPMENT CO., LTD.*

FA Abandonment or withdrawal